Dyadic International (DYAI) Osake Kurssi
Dyadic International Kurssi
Dyadic Internationaln liikevaihto on supistunut 12,4 % vuodessa viimeisten 19 vuoden aikana 1,23 M USD:een. Osakekohtainen tulos on kasvanut 51,5 % vuodessa viimeisten 6 vuoden aikana. Dyadic Internationaln nettomarginaali on nyt −597,6 %, laskenut −543,7 %:sta muutama vuosi sitten.
Dyadic International osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Dyadic International liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Dyadic International -osakkeesta
The main competitors of Dyadic International Inc in the market are companies such as Novozymes A/S, Codexis Inc, and Danisco A/S.
Dyadic International Inc. is a biotechnology company that operates under a unique business model. The company primarily focuses on developing and commercializing innovative enzyme technologies. These enzymes are utilized in various industries such as animal health, biofuels, food and beverages, and industrial applications. With a strong emphasis on research and development, Dyadic International Inc. aims to create sustainable and cost-effective solutions for its customers. By harnessing the power of its proprietary C1 gene expression platform, the company strives to deliver high-performing enzymes that offer numerous benefits in terms of efficiency, environmental sustainability, and overall performance.
Dyadic International Inc is primarily active in the biotechnology industry.
Dyadic International Inc is a biotechnology company founded in 1979 in Jupiter, Florida. The company specializes in developing and producing enzymes and other proteins for various industries, including pharmaceuticals, animal health, and biofuels. With four decades of experience, Dyadic has built a strong reputation for its proprietary C1 gene expression platform, which enables efficient production of biologics at a lower cost. The company has established partnerships with leading organizations worldwide to further advance its technology and product portfolio. Dyadic International Inc continues to strive for innovation and contribute to the biotechnology industry through its cutting-edge research and development efforts.
Dyadic International Inc has achieved several significant milestones. The company successfully developed its proprietary C1 gene expression platform, which is highly efficient in producing biologic vaccines, therapeutic proteins, and other biopharmaceutical products. Dyadic has formed strategic partnerships with leading global companies to utilize the C1 technology in the production of vaccines for COVID-19, potentially addressing the global supply shortage. Additionally, the company has received numerous accolades and recognition for its innovative approach and contributions to the biotechnology industry. Dyadic International Inc continues to make advancements in the field, positioning itself as a key player in the biopharmaceutical sector.
Dyadic International Inc is primarily present in the United States and Europe.
Dyadic International Inc represents a set of core values and corporate philosophy that drive its operations. With a focus on innovation and technological advancements, Dyadic aims to deliver cutting-edge solutions in the field of biotechnology. The company's core values include integrity, collaboration, and a commitment to excellence. By fostering an inclusive and diverse environment, Dyadic emphasizes teamwork and cooperation to achieve its goals. Dyadic International Inc strives to create value for its stakeholders by leveraging its proprietary C1 gene expression system and continuing to advance the biopharmaceutical industry through continuous research and development efforts.
7 analyytikkoa arvioi tällä hetkellä Dyadic International-osaketta: 6 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Dyadic International-yhtiöltä 6,59 M USD liikevaihtoa ja −0,13 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Dyadic International-osake noteerataan hintaan 0,36 EUR (0,41 USD).
Dyadic International-osake (DYAI) on listattuna 1 pörssissä, muun muassa: NASDAQ (DYAI).
Dyadic International Inc is a company specializing in the development and manufacturing of biotechnological products. The company's business model is based on the use of proprietary technologies and collaboration with partners and customers. The company has three main business areas: 1. Biopharmaceuticals Dyadic has developed a proven platform for the production of proteins and antibodies that can be used in many medical applications. The company is working with various partners on the development of new therapies for diseases such as cancer, autoimmune diseases, and metabolic disorders. 2. Enzymes and cellulose The company also produces enzymes and cellulose-rich products used in the food and paper industries. For example, enzymes are used in the production of foods such as beer, cheese, and bread. The company is also working on finding new applications for the use of cellulose in healthcare and medical products. 3. Research and development Dyadic is also engaged in research and development of new technologies in biotechnology. The company is working on the development of DNA technologies and enzymes that can be applied in various industries. Dyadic also operates a combination of direct sales and partnerships. The company does not have its own marketing or sales department, but works with partners to sell its products and technologies. Dyadic is also interested in forming partnerships with other companies and academic research institutions to develop new technologies and products. Summary Dyadic International Inc is a biotechnology company specializing in the development and manufacturing of biopharmaceutical products, enzymes, and cellulose-containing products. The company has proprietary technologies that can be used in many applications and collaborates with partners and customers to develop new products and technologies. The company's focus is on researching and developing new technologies and applications.
odotettu liikevaihto Dyadic International on 6,59 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Dyadic International on −4,10 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Dyadic International:n hinta-voitto-suhde (P/E) on tällä hetkellä −3,26. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Dyadic International-osakkeen arvostusta.
Dyadic International:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,03. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Dyadic International-osakkeen arvostuskennuslukuna.
Dyadic International:n Eulpool-laatuscore on 3/10.
Dyadic International:n ISIN on US26745T1016. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Dyadic International:n WKN on A0JK0A. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Dyadic International:n ticker on DYAI. Tämä pörssinoteeraus käytetään Dyadic International-osakkeiden kauppaan pörssissä.
Dyadic International osake
Dyadic International vertaisryhmä
Dyadic International Ticker
Dyadic International FIGI
Kaikki tunnusluvut ja syvällinen analyysi Dyadic International:sta
Meidän osakeanalyysimme Dyadic International-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Dyadic International:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: